Alprazolam: Difference between revisions
(Created page with "==General== *Type: Benzodiazepines *Dosage Forms: *Common Trade Names: Xanax ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== *Drug Ratings in Pregnancy|...") |
ClaireLewis (talk | contribs) No edit summary |
||
| (10 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: [[Benzodiazepines]] | *Type: [[Benzodiazepines]] | ||
*Dosage Forms: | *Dosage Forms: ODT Immediate Release - 0.25, 0.5, 1, 2mg tablets. Extended Release - 0.5, 1, 2, 3mg tablets, Oral liquid, 1mg/mL | ||
*Common Trade Names: Xanax | *Common Trade Names: Xanax, Xanax XR, Niravam | ||
==Adult Dosing== | ==Adult Dosing== | ||
*[[Anxiety]]: 0.25-0.5mg PO TID, Max: 4mg/day | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
<18 years old: Not recommended | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: D | ||
*Lactation: | *[[Lactation risk]]: L3<ref>Armstrong C. "ACOG Guidelines on Psychiatric Medication Use During Pregnancy and Lactation". Am Fam Physician. 2008 Sep 15;78(6):772-778.</ref> | ||
*Renal Dosing | *Renal Dosing: no adjustment | ||
*Hepatic Dosing: | |||
*Hepatic Dosing | **Start at min dose, slowly up-titrate dose amount and frequency to max of 4mg/day | ||
** | |||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*Sleep apnea | |||
*Concomitant Alcohol use | |||
*Concomitant CNS depressant use | |||
*Elderly | |||
*Abuse history | |||
*Hepatic disease (decreased clearance) | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Respiratory depression/arrest | |||
*Abuse | |||
*Hypotension | |||
*[[Syncope]] | |||
*Hepatotoxicity | |||
*[[Angioedema]] | |||
*[[Steven-Johnson Syndrome]] | |||
===Common=== | ===Common=== | ||
*Altered mental status (drowsiness, fatigue, amnesia, impaired concentration, impaired coordination) | |||
*Urinary incontinence/retention | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: ~11hr | ||
*Metabolism: | *Metabolism: Hepatic via CYP450:3A4 substrate | ||
*Excretion: | *Excretion: Urine | ||
*Mechanism of Action: | *Mechanism of Action: Enhances GABA effects by binding to specific benzodiazepine receptor | ||
==See Also== | ==See Also== | ||
== | ==References== | ||
<references/> | <references/> | ||
[[Category: | [[Category:Pharmacology]] [[Category:Psychiatry]] | ||
Latest revision as of 16:44, 19 September 2019
General
- Type: Benzodiazepines
- Dosage Forms: ODT Immediate Release - 0.25, 0.5, 1, 2mg tablets. Extended Release - 0.5, 1, 2, 3mg tablets, Oral liquid, 1mg/mL
- Common Trade Names: Xanax, Xanax XR, Niravam
Adult Dosing
- Anxiety: 0.25-0.5mg PO TID, Max: 4mg/day
Pediatric Dosing
<18 years old: Not recommended
Special Populations
- Pregnancy Rating: D
- Lactation risk: L3[1]
- Renal Dosing: no adjustment
- Hepatic Dosing:
- Start at min dose, slowly up-titrate dose amount and frequency to max of 4mg/day
Contraindications
- Allergy to class/drug
- Sleep apnea
- Concomitant Alcohol use
- Concomitant CNS depressant use
- Elderly
- Abuse history
- Hepatic disease (decreased clearance)
Adverse Reactions
Serious
- Respiratory depression/arrest
- Abuse
- Hypotension
- Syncope
- Hepatotoxicity
- Angioedema
- Steven-Johnson Syndrome
Common
- Altered mental status (drowsiness, fatigue, amnesia, impaired concentration, impaired coordination)
- Urinary incontinence/retention
Pharmacology
- Half-life: ~11hr
- Metabolism: Hepatic via CYP450:3A4 substrate
- Excretion: Urine
- Mechanism of Action: Enhances GABA effects by binding to specific benzodiazepine receptor
See Also
References
- ↑ Armstrong C. "ACOG Guidelines on Psychiatric Medication Use During Pregnancy and Lactation". Am Fam Physician. 2008 Sep 15;78(6):772-778.